Nuclear Medicine: Current Status and Trends in Radionuclide Therapy
https://doi.org/10.37174/2587-7593-2025-8-4-38-49
Abstract
Nuclear medicine is currently undergoing a tremendous boom. The use of radiopharmaceuticals (RPHs) for the diagnostics & treatment of various diseases in routine medical practice is becoming increasingly widespread, significantly enhancing the overall efficacy of the treatment process. Currently the possibility to manufacture radiopharmaceuticals in-house, at hospital radiopharmacies, provides the domestic hospitals with the opportunity to use new highly effective, yet unregistered, radiopharmaceticals. They are based on radionuclides produced in Russia (such as 177Lu, 225Ac etc.)
Supporting agencies: The study had no sponsorship.
About the Authors
V. V. Krylov
A. Tsyb Medical Radiological Research Center (MRRC); Isotope JSC
Russian Federation
Competing Interests:
Russian Federation
Valery V. Krylov
249031, Kaluga region, Obninsk, Marshal Zhukov st., 10
Pogodinskaya St. 22, Moscow 119435
Competing Interests:
Not declared
O. V. Valzdorf
Isotope JSC
Russian Federation
Competing Interests:
Russian Federation
Olga V. Valzdorf
Pogodinskaya St. 22, Moscow 119435
Competing Interests:
Not declared
T. Yu. Kochetova
A. Tsyb Medical Radiological Research Center (MRRC)
Russian Federation
Competing Interests:
Russian Federation
Tatiana Yu. Kochetova
249031, Kaluga region, Obninsk, Marshal Zhukov st., 10
Competing Interests:
Not declared
References
1. Medraysintell, 2022, https://www.pr.com/press-release/869480
2. Precedence research, 2025, https://www.precedencere search.com/radiopharmaceuticals-market
3. Rumiantsev PO, Korenev SV. The history of radioiodine therapy beginnings. Clinical and Experimental Thyroidology. 2015;11(4):51–55. (In Russ.). https://doi.org/10.14341/ket2015451-55.
4. Subbotina NN, Dolgopolov IS, Boyarshinov VK, et al. High Dose Chemotherapy with MIBG I131 in Treatment of Patients with Neuroblastoma of High-Risk: a Cohort Study. Oncopediatrics. 2019;6(2):106-12. (In Russ.). https://doi.org/10.15690/ONCO.V6I2.2022.
5. Petriev VM, Skvortsov VG, Krylov VV, Kanygin VV, Ruziev RD, Zverev AV, Antonjuk AV, Lebedeva VS. Rhenium-188 radiopharmaceutical for therapy of bone diseases and method for producing it. Patent № RU 2567728 C1, 10.11.2015. Application № 2014122000/15, 30.05.2014.
6. Krylov VV, Kochetova TYu. Radionuclide Therapy with Rhenium 188 HEDP for the Treatment of Patients with Bone Metastases. Medical Radiology and Radiation Safety. 2014;59(6):54-62. (In Russ.).
7. Kochetova TYu, Krylov VV, Smolyarchuk MY, Voloznev LV, Lunev AS. 188Re zoledronic acid is a new Russian radiopharmaceutical to treat bone metastases: the Įrst clinical experience. Oncology bulletin of the Volga Region. 2014;3:41-47. (In Russ.).
8. Krylov VV, Legkodimova NS, Kochetova TYu, et al. Radioligand therapy with 177Lu-DOTA-PSMA in metastatic castrationresistant prostate cancer. Pharmacokinetics, safety, antitumour eĸcacy. Diagnostic Radiology and Radiotherapy. 2022;4(13):75-85. (In Russ.). https://doi.org/10.22328/2079-5343-2022-13-4-75-85.
9. Kochetova TYu, Krylov VV, Ivanov SA, Kaprin AD. 225Ac PSMA 617 therapy in metastatic castration resistant prostate cancer. Siberian Journal of Oncology. 2024;23(6):32-40. (In Russ.). https://doi.org/10.21294/1814-4861-2024-23-6-32-40.
Review
For citations:
Krylov V.V., Valzdorf O.V., Kochetova T.Yu. Nuclear Medicine: Current Status and Trends in Radionuclide Therapy. Journal of oncology: diagnostic radiology and radiotherapy. 2025;8(4):38-49. (In Russ.) https://doi.org/10.37174/2587-7593-2025-8-4-38-49
Views:
354
JATS XML
Email this article 